Shui On Leung

Shui On Leung

Chief Executive Officer presso SINOMAB BIOSCIENCE LIMITED

Patrimonio netto: 26 M $ in data 31/03/2024

64 anni
Health Technology
Consumer Services

Profilo

Shui On Leung is the founder of Sinomab Bioscience Ltd., which was founded in 2001.
He holds the title of Chairman & Chief Executive Officer at Sinomab Bioscience Ltd.
from 2003 to the present.
Dr. Leung is currently the Director at Hong Kong Genome Institute.
In the past, he worked as the Associate Director-Molecular Biology Department at Immunomedics, Inc. from 1991 to 2000.
From 2000 to 2003, he served as the Managing Director at The Hong Kong Institute of Biotechnology Ltd.
Dr. Leung was also the Director at Novelmab Ltd.
from 2011 to 2018.
Dr. Leung obtained a doctorate degree from the University of Oxford in 1990.
He also holds undergraduate and graduate degrees from The Chinese University of Hong Kong, which were conferred in 1986.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
31/01/2024 129 729 200 ( 11.88% ) 26 M $ 31/03/2024

Posizioni attive di Shui On Leung

SocietàPosizioneInizio
SINOMAB BIOSCIENCE LIMITED Chief Executive Officer 01/01/2003
Hong Kong Genome Institute Director/Board Member -
Tutte le posizioni attive di Shui On Leung

Precedenti posizioni note di Shui On Leung

SocietàPosizioneFine
Novelmab Ltd. Director/Board Member 01/07/2018
The Hong Kong Institute of Biotechnology Ltd. Chief Executive Officer 01/08/2003
IMMUNOMEDICS, INC. Corporate Officer/Principal 01/07/2000
Vedi nel dettaglio l'esperienza di Shui On Leung

Formazione di Shui On Leung

University of Oxford Doctorate Degree
The Chinese University of Hong Kong Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Shui On Leung

Relazioni

100 +

Relazioni di 1° grado

7

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa1
SINOMAB BIOSCIENCE LIMITED

Health Technology

Aziende private4

Health Technology

The Hong Kong Institute of Biotechnology Ltd.

Novelmab Ltd.

Hong Kong Genome Institute

Vedi le connessioni aziendali